Cite
HARVARD Citation
Martin, M. et al. (n.d.). Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet oncology. 18 (12), pp. 1688-1700. [Online].